Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899448 | 0.85 | HTT (0.56) | GAASMN1; SMN2TSHRKMT2AHPGD | |
| SCHEMBL12187440 | 0.83 | ALDH1A1 (0.50) | ALDH1A1GAASMN1; SMN2NPSR1HSP90AA1 | |
| SCHEMBL7121916 | 0.83 | SMN1; SMN2 (0.77) | ALDH1A1GAASMN1; SMN2NPSR1TSHR | |
| SCHEMBL14803568 | 0.83 | L3MBTL1 (0.60) | ALDH1A1TSHRTP53KMT2AHPGD | |
| SCHEMBL12305558 | 0.79 | HSD11B1 (0.49) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL10013747 | 0.79 | HTT (0.72) | ALDH1A1GAASMN1; SMN2NPSR1PKM | |
| SCHEMBL14803634 | 0.78 | KMT2A (0.66) | ALDH1A1SMN1; SMN2TSHRKMT2AHPGD | |
| SCHEMBL20826987 | 0.78 | RAB9A (0.65) | ALDH1A1GAATSHRKMT2A | |
| SCHEMBL3758627 | 0.78 | ALDH1A1 (0.63) | ALDH1A1GAASMN1; SMN2NPSR1TSHR | |
| SCHEMBL29956307 | 0.78 | ALDH1A1 (0.63) | ALDH1A1GAASMN1; SMN2NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169246-B2 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-10-27 | — | — | US | disclosed |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7737154-B2 | CRF receptor antagonists and methods relating thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2010-06-15 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | ALDH1A1 1525/4885GAA 2306/4885SMN1; SMN2 1756/4885 |
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, COQ8A, CYP1A2 | ALDH1A1 88/4885GAA 1467/4885SMN1; SMN2 1132/4885 |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, CYP1A2, COQ8A | ALDH1A1 97/4885GAA 1631/4885SMN1; SMN2 1192/4885 |
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | ALDH1A1 3218/4885GAA 1795/4885SMN1; SMN2 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.